Since December 22, 2025 Wegovy has come in two forms under one label. The injection is once a week and needs a fridge. The tablet is once a day and needs an empty stomach. The label treats them as two routes to the same place and gives rules for crossing between them.
| Wegovy injection (once weekly) | Wegovy tablets (once daily) | |
|---|---|---|
| Escalation | 0.25, 0.5, 1, 1.7 mg, 4 weeks each (16 weeks) | 1.5, 4, 9 mg, 30 days each (90 days) |
| Maintenance | 2.4 mg (recommended) or 1.7 mg; 7.2 mg option in adults | 25 mg once daily |
| Indications | Weight (adults and 12 and older), cardiovascular risk reduction, MASH | Weight (adults), cardiovascular risk reduction; not adolescents, not MASH |
| Routine | Any time of day, with or without food, same day each week | Morning, empty stomach, up to 4 oz water, then 30 minutes with nothing by mouth |
| Missed dose | Take if the next dose is more than 48 hours away, else skip | Skip; next tablet the following day; never two in a day |
| Pivotal weight trial | STEP 1: -14.9% vs -2.4% at 68 weeks (difference 12.4 points) | OASIS 4: -13.6% vs -2.2% at 64 weeks (difference 11.4 points) |
| GI adverse events | Label: nausea 44% vs 16%, vomiting 24% vs 6% | OASIS 4: any GI event 74.0% vs 42.2% |
| Storage | Refrigerate; up to 28 days at up to 30°C before cap removal | Room temperature, original bottle, dry |
| Self-pay (April 2026 sheet) | $349 per month at 0.25 to 2.4 mg | $149, $199, $299, $299 by step; $299 at 25 mg |
The trials are parallel, not head to head
STEP 1 (PubMed 33567185): 1,961 adults without diabetes, 68 weeks, 2.4 mg weekly, 14.9% versus 2.4%, difference 12.4 points (95% CI 11.5 to 13.4). OASIS 4 (PubMed 40934115): 307 adults with overweight or obesity, 64 weeks, 25 mg daily, 13.6% versus 2.2%, difference 11.4 points (95% CI 9.0 to 13.9). The confidence intervals overlap. Novo Nordisk's announcement quotes 16.6% for the tablet "when treatment was adhered to", an on-treatment figure; the injection's equivalent on-treatment figures in the STEP papers are also higher than the primary estimands. Comparing like with like, the two forms land close.
The tablet trial was a fifth the size of the injection trial, and the tablet has no long-duration trial equivalent to STEP 5's two years. That is the honest asymmetry in the evidence, not a difference in effect.
The routine is the real difference
A weekly injection asks for one decision a week and a refrigerator. A daily tablet asks for the same 30-minute fasting window every morning, up to 4 ounces of plain water and no other liquid, no coffee, no other pills, for the rest of your life on it. The label is specific because the absorption depends on it. People who already take a morning medicine with breakfast will need to rearrange; people who travel across time zones will find the tablet simpler to carry and harder to time.
Missed doses show the same asymmetry. A missed injection has a 48-hour rule and a day's grace; a missed tablet is simply skipped, and the label forbids doubling up. The missed-dose helper handles both.
Switching, per the label
Injection to tablet. Patients on 2.4 mg injection for cardiovascular risk reduction or weight reduction may switch to 25 mg tablets, starting the tablet one week after the last injection, straight to the maintenance dose with no tablet escalation.
Tablet to injection. Start 2.4 mg injection the day after the last 25 mg tablet. If the tablet was stopped for intolerance, the label says to consider 1.7 mg injection. For people with type 2 diabetes who need more weight reduction on the tablet, the label suggests switching to 1.7 mg injection and following the injection escalation.
The label's own escalation guidance (a 16-week climb for the injection, 90 days for the tablet) does not apply to a switch at maintenance. The titration planner dates a fresh start on either form; it does not model a switch, because the label reduces that to a single day or a single week.
Who can have which
The tablet's indications are adults only, for weight reduction and cardiovascular risk reduction. Adolescents aged 12 and older and adults with MASH are on the injection's label and not the tablet's. The 7.2 mg option exists only as an injection.
Price
On Novo Nordisk's April 2026 self-pay sheet the tablet at maintenance ($299 for 25 mg) is $50 a month less than the injection ($349 for 2.4 mg), and the tablet's first two steps ($149 and $199) are below the injection's $199 introductory offer. The cost view applies these with their dates. There is no compounded equivalent of the Wegovy tablet with any trial behind it; compounded semaglutide is not FDA approved and OASIS 4 tested Novo Nordisk's formulation only. For what the Tirzepatide Hub covers on the injection-only alternative, and for FormBlends' own compounded semaglutide, follow the links.
Questions people ask
Which works better?
They have not been compared head to head. STEP 1 and OASIS 4 were different trials with different populations and durations. Their placebo-adjusted results (12.4 and 11.4 percentage points) are in the same range, and Novo Nordisk's on-treatment figure for the tablet (16.6%) is likewise similar to the injection's. Treat them as comparable, not ranked.
How do I switch from the pen to the pill?
The label says patients on 2.4 mg injection may switch to 25 mg tablets, starting the tablet one week after the last injection. There is no tablet re-escalation in that direction.
And back?
Start 2.4 mg injection the day after the last 25 mg tablet. If the 25 mg tablet was not tolerated, the label says to consider 1.7 mg injection instead.
Sources
- Wegovy (semaglutide) injection and tablets prescribing information, revised 6/2026, sections 2.3 to 2.5, DailyMed Accessed September 4, 2026.
- Wharton S et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med 2025. PubMed 40934115 Accessed September 4, 2026.
- Wilding JPH et al. STEP 1. N Engl J Med 2021. PubMed 33567185 Accessed September 4, 2026.
- NovoCare Pharmacy Wegovy price guide, April 2026 Accessed September 4, 2026.
Canonical URL: https://formblendssemaglutide.com/compare/wegovy-injection-vs-tablet. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.